Total Endovascular Aortic Arch Repair: From Dream to Reality.


Journal

Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208

Informations de publication

Date de publication:
02 Mar 2022
Historique:
received: 25 01 2022
revised: 24 02 2022
accepted: 25 02 2022
entrez: 26 3 2022
pubmed: 27 3 2022
medline: 31 3 2022
Statut: epublish

Résumé

The gold-standard therapy for the treatment of aortic arch pathologies is conventional open surgery. Recently, total endovascular aortic arch replacement with branched stent-grafts has been introduced into clinical practice with the aim of reducing invasiveness especially in selected high-risk patients. The aim of this review is to describe the two most commonly used branched devices for endovascular arch stent-grafting: Nexus (Endospan, Herzlia, Israle) and RelayBranch (Terumo Aortic, Glasgow, United Kingdom). Nexus is a CE-certified off-the-shelf, single branch, double stent graft system. It consists of two different components: a main module for the aortic arch and the descending aorta with a side-branch for the brachiocephalic artery (BCA), and a curved module for the ascending aorta that lands into the sino-tubular junction and connects to the main module through a side-facing self-protecting sleeve. Nexus may be used in urgent-emergency cases and also in patients with only one suitable supra-aortic target vessel but, on the other hand, it makes cerebral blood flow dependent on one source vessel only. The RelayBranch Thoracic Stent-Graft System is a custom made, double branched endograft with a wide window on its superior portion to accommodate two inner tunnels for BCA and left common carotid artery connection; bilateral cervical accesses are generally used to advance guidewires for catheterization of the inner tunnels in a retrograde fashion. RelayBranch can be customized on every patient's specific anatomy and provides a double blood source for the brain, but it cannot be used in urgent-emergency conditions. Therefore, in order to optimize outcomes, the choice of the most appropriate device should be made considering pros and cons of each system and patient's anatomy by an experienced aortic team. In conclusion, total endovascular aortic arch exclusion is a promising reality in selected high-risk patients.

Identifiants

pubmed: 35334549
pii: medicina58030372
doi: 10.3390/medicina58030372
pmc: PMC8948628
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

JTCVS Tech. 2020 Apr 28;3:1-8
pubmed: 34317796
Semin Thorac Cardiovasc Surg. 2019 Summer;31(2):146-152
pubmed: 30633977
J Vasc Surg. 2015 Dec;62(6):1473-8
pubmed: 26365663
J Vasc Surg. 2013 Nov;58(5):1171-7
pubmed: 23746832
J Card Surg. 2019 Jul;34(7):641-644
pubmed: 31212361
Eur J Cardiothorac Surg. 2016 Nov;50(5):940-948
pubmed: 27229666
J Vasc Surg. 2019 Sep;70(3):672-682.e1
pubmed: 30871889
Korean J Thorac Cardiovasc Surg. 2017 Feb;50(1):1-7
pubmed: 28180096
JTCVS Tech. 2020 Sep 26;4:17-25
pubmed: 34317956
J Thorac Cardiovasc Surg. 2013 Mar;145(3 Suppl):S103-9
pubmed: 23410765
Ann Surg. 2021 Mar 04;:
pubmed: 33714965
J Vasc Surg. 2016 Sep;64(3):592-9
pubmed: 27313087
Eur J Vasc Endovasc Surg. 2020 Oct;60(4):531-538
pubmed: 32312668
Ann Cardiothorac Surg. 2013 May;2(3):339-46
pubmed: 23977603
J Heart Valve Dis. 2015 Sep;24(5):528-30
pubmed: 26897830
J Endovasc Ther. 2015 Feb;22(1):116-21
pubmed: 25775691
J Thorac Cardiovasc Surg. 2014 Oct;148(4):1709-16
pubmed: 24685375
J Vasc Surg. 2010 Oct;52(4 Suppl):91S-9S
pubmed: 20724097
Clin Interv Aging. 2019 Oct 25;14:1829-1840
pubmed: 31749612
Ann Cardiothorac Surg. 2018 May;7(3):397-405
pubmed: 30155419
Eur J Vasc Endovasc Surg. 2019 Feb;57(2):165-198
pubmed: 30318395
Ann Vasc Surg. 2020 May;65:54.e1-54.e4
pubmed: 31981683
Ann Thorac Surg. 2020 Nov;110(5):e371-e373
pubmed: 32376356

Auteurs

Augusto D'Onofrio (A)

Division of Cardiac Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.

Raphael Caraffa (R)

Division of Cardiac Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.

Giorgia Cibin (G)

Division of Cardiac Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.

Michele Antonello (M)

Division of Vascular Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.

Gino Gerosa (G)

Division of Cardiac Surgery, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH